mirna Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples
|
|
- Lesley Underwood
- 5 years ago
- Views:
Transcription
1 Imaging, Diagnosis, Prognosis Clinical Cancer Research mirna Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples Katleen De Preter 1, Pieter Mestdagh 1,Jo elle Vermeulen 1, Fjoralba Zeka 1, Arlene Naranjo 3, Isabella Bray 4, Victoria Castel 5, Caifu Chen 7, Elzbieta Drozynska 8, Angelika Eggert 9, Michael D. Hogarty 10, Ewa I_zycka-Swieszewska 8, Wendy B. London 11, Rosa Noguera 6, Marta Piqueras 6, Kenneth Bryan 4, Benjamin Schowe 12, Peter van Sluis 13, Jan J. Molenaar 13, Alexander Schramm 9, Johannes H. Schulte 9, Raymond L. Stallings 4, Rogier Versteeg 13, Genevieve Laureys 2, Nadine Van Roy 1, Frank Speleman 1, and Jo Vandesompele 1 Abstract Purpose: More accurate assessment of prognosis is important to further improve the choice of risk-related therapy in neuroblastoma (NB) patients. In this study, we aimed to establish and validate a prognostic mirna signature for children with NB and tested it in both fresh frozen and archived formalin-fixed paraffin-embedded (FFPE) samples. Experimental Design: Four hundred-thirty human mature mirnas were profiled in two patient subgroups with maximally divergent clinical courses. Univariate logistic regression analysis was used to select mirnas correlating with NB patient survival. A 25-miRNA gene signature was built using 51 training samples, tested on 179 test samples, and validated on an independent set of 304 fresh frozen tumor samples and 75 archived FFPE samples. Results: The 25-miRNA signature significantly discriminates the test patients with respect to progressionfree and overall survival (P < 001), both in the overall population and in the cohort of high-risk patients. Multivariate analysis indicates that the mirna signature is an independent predictor of patient survival after controlling for current risk factors. The results were confirmed in an external validation set. In contrast to a previously published mrna classifier, the 25-miRNA signature was found to be predictive for patient survival in a set of 75 FFPE neuroblastoma samples. Conclusions: In this study, we present the largest NB mirna expression study so far, including more than 500 NB patients. We established and validated a robust mirna classifier, able to identify a cohort of highrisk NB patients at greater risk for adverse outcome using both fresh frozen and archived material. Clin Cancer Res; 17(24); Ó2011 AACR. Authors' Affiliations: 1 Center for Medical Genetics; 2 Department of Paediatric Hematology and Oncology, Ghent University Hospital, Ghent, Belgium; 3 Children's Oncology Group, University of Florida, Gainesville, Florida; 4 Department of Cancer Genetics, Royal College of Surgeons in Ireland, and National Children's Research Centre, Dublin, Ireland; 5 Pediatric Oncology Unit, Hospital La Fe, Valencia; 6 Department of Pathology, Medical School, University of Valencia, Valencia, Spain; 7 Applied Biosystems, Foster City, California; 8 Department of Pediatric Haematology, Oncology and Endocrinology, Medical University of Gdansk, Gdansk, Poland; 9 Department of Pediatric Oncology and Haematology, University Children's Hospital Essen, Essen, Germany; 10 Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; 11 Children's Oncology Group, Children's Hospital Boston/Dana-Farber Harvard Cancer Center, Boston, Massachusetts; 12 Department of Computer Science, Technische Universit at Dortmund, Dortmund, Germany; and 13 Department of Human Genetics, Academic Medical Center, Amsterdam, the Netherlands Note: Supplementary data for this article are available at Clinical Cancer Research Online ( K. De Preter, P. Mestdagh, and J. Vermeulen are shared first authors. Corresponding Author: Jo Vandesompele, Center for Medical Genetics Ghent (CMGG), Ghent University Hospital, Medical Research Building (MRB), 2nd floor, Room 1255, De Pintelaan 185, B-9000 Ghent, Belgium. Phone: ; Fax: ; Joke.Vandesompele@UGent.be doi: / CCR Ó2011 American Association for Cancer Research. Introduction Given the clinical heterogeneity of neuroblastoma (NB), accurate prognostic classification of patients with this tumor is one of the major challenges to improve the choice of risk-related therapy. Clinical experience with the currently used risk stratification systems suggests that the stratification of patients for treatment is useful (1). Nevertheless, patients with the same clinicopathologic and genetic parameters, receiving the same treatment, can have markedly different clinical courses. On the basis of the assumption that differences in outcome are mainly driven through underlying genetic and biological characteristics, gene expression studies have been undertaken to detect new prognostic markers and to establish gene expression-based classifiers for improved neuroblastoma patient care. Recently, we established a messenger RNA (mrna) gene expression classifier and validated the performance of this classifier in 2 independent patient cohorts (2). However, we could clearly show an adverse effect of poor RNA quality on the performance of the 59-mRNA classifier (3) Clin Cancer Res; 17(24) December 15, 2011
2 Prognostic MicroRNA Signature for Neuroblastoma Patients Translational Relevance Through one of the largest mirna expression studies on patients, we have developed and validated a mirna expression signature that is predictive for neuroblastoma patient outcome. This 25-miRNA signature allows to identify a cohort of neuroblastoma patients with increased risk for adverse outcome, independent of current clinical, and molecular risk factors. Importantly, this classifier conducts equally well in archived (formalin-fixed paraffin-embedded) material as in fresh frozen samples. Moreover, it allows to further stratify patients within the current high-risk population and as such identifies neuroblastoma patients that are at ultrahigh-risk. In a comparative analysis, we show that our reported 25-miRNA signature outperforms previously published mirna signatures in terms of accurate patient classification. Our results were validated on 2 independent patient cohorts and indicate that the use of mirna expression signatures can substantially improve risk stratification of neuroblastoma patients, especially within the current high-risk population. Improved patient classification is expected to result in more appropriate selection of therapeutic regimens. Recently, an important class of small noncoding RNAs (ncrna) regulating mrna expression, termed micrornas (mirna), have been shown to be implicated in various cancers, including NB (4, 5) and are known to be less sensitive to RNA degradation processes. Here, we set out to conduct an in-depth study on an unprecedentedly large cohort of primary untreated neuroblastoma tumors to unequivocally establish the possible prognostic power of mirna classifiers. To this purpose, we tested and validated the performance of a 25-miRNA prognostic classifier in 3 independent patient cohorts including both fresh frozen and archived formalin-fixed paraffin-embedded (FFPE) material. Materials and Methods Patients and tumor samples The first train-test cohort consisted of 230 NB patients (27 from Ghent, Belgium, 54 from Essen, Germany, 31 from Valencia, Spain, 43 from Dublin, Ireland, and 75 from Amsterdam, the Netherlands). Patients were only included if primary untreated NB tumor RNA (at least 60% tumor cells and confirmed histologic diagnosis of NB) was present. All patients provided consent and were enrolled on at least one study: International Society of Paediatric Oncology, European Neuroblastoma Group (SIOPEN), the Gesellschaft fuer Paediatrische Onkologie und Haematologie (GPOH), the Children s Oncology Group (COG-United States) study, Dutch Childhood Oncology Group (DCOG, Amsterdam) or the Our Lady s Children s Hospital (Dublin). The median follow-up was 68 months (range months), and was greater than 36 months for most patients without an event (114/139 ¼ 82%). At the time of analysis, 156 of 230 patients were alive. All patients were treated according to similar protocols. The validation cohort consisted of 304 patients from the COG: including 128 cases with an event and 189 patients without an event, with at least 36 months of follow-up. All laboratory analyses were done blinded to clinical and outcome data. All patients provided consent and were enrolled on at least one COG study, and all participating institutions had Institutional Review Board approval to take part in the COG studies. The FFPE validation cohort (43 samples from Gdansk, Poland and 33 samples from Valencia, Spain) contained 28 cases with an event and 47 cases without an event. Eighty percent (42/52) of the patients that survived had at least 36 months of follow-up. This study was approved by the Ghent University Hospital Ethical Committee (EC2008/159). mirna expression profiling Total RNA was extracted in different national reference laboratories using a silica gel-based membrane purification method (mirnaeasy kit, Qiagen) or by a phenol-based method (TRIzol reagent, Life Technologies) according to the manufacturer s instructions. As published earlier by Wang and colleagues, there is a high correlation in mirna expression between protocols that are based on the phenol/ chloroform procedure (6). Therefore, we do not expect an effect of RNA isolation method on mirna expression results. A separate extraction protocol was applied to extract total RNA from the FFPE cohort (MasterPure RNA purification kit, Experion) according to manufacturers instructions. For fresh-frozen samples, reverse transcription (starting from 20 ng of total RNA) and mirna expression profiling of 430 human mirnas was done as described earlier (7). For FFPE samples, reverse transcription was done using 60 ng of total RNA. Samples from both validation cohorts (fresh frozen and FFPE material) were only profiled for the selected set of 25 prognostic mirnas. Data normalization was done using the mean expression of 4 selected stably expressed reference mirnas (hsa-mir-125a, hsamir-99b, hsa-mir-423, and hsa-mir-425) according to Mestdagh and colleagues (8). The data sets from the different centers were independently standardized (mean centered and autoscaled; ref. 9). mirna expression data and clinical sample annotation are available in rdml-format (10; Supplementary File S1 3). mrna expression profiling Expression analysis of 59 prognostic mrna genes was done according to a procedure described elsewhere (2). In brief, qrt-pcr was used to measure 59 prognostic genes and 5 reference sequences. Real-time qpcr was done in a 384-well plate instrument (CFX384, Bio-Rad). Biogazelle s qbase PLUS software was used for data analysis (normalization, error propagation, inter-run calibration). Results were standardized (mean centered and autoscaled). mrna Clin Cancer Res; 17(24) December 15,
3 De Preter et al. expression data are available in rdml-format (Supplementary File S1). Statistical analysis For data analysis, the tumor samples were divided into a training set and a test set. The training set consisted of 51 samples randomly selected from 2 patient subgroups with maximally divergent clinical courses: 24 low-risk patients with INSS stage 1, 2, or 4S without MYCN amplification and with progression-free survival (PFS) time of at least 1,000 days and 27 deceased high-risk patients older than 12 months at diagnosis with INSS stage 4 tumor (irrespective of the MYCN gene status) or with INSS stage 2 or 3 tumor with MYCN amplification. Univariate logistic regression analysis was used to select the top 25 mirna genes with prognostic relevance in NB, that is, the mirnas with the lowest P value in a model testing mirna expression levels (below or above the median expression) versus overall survival (OS). The 25 mirna and 59 mrna expression signatures were built using the same training set, tested on the remaining 179 samples, and validated in a blind manner on the validation cohort of 304 COG samples. For the test cohort, the R-language for statistical computing (version 2.9.0) was used to train and test the prognostic signature using the Prediction Analysis of Microarrays (PAM) method (11; Bioconductor MCR estimate package; 12), to evaluate its performance by receiver operating characteristic (ROC) curve and area under the curve (AUC) analyses (ROCR package), and for Kaplan Meier survival analyses (survival package). Multivariate logistic regression analyses were done using PASW Statistics (version 18). Currently used risk factors such as age at diagnosis (12 months vs. <12 months), International Neuroblastoma Staging System (INSS) stage (stage 4 vs. not stage 4), and MYCN status (amplified vs. not amplified) were tested, and variables with P values less than 5 were retained in the model. Because an interaction between the signature and risk factors was not expected to occur, interaction terms were not included in the models. For ROC and multivariate analyses, only patients with an event and patients with sufficient follow-up time (36 months) if no event occurred were included, because 95% of events in NB are expected to occur within the first 36 months after diagnosis. Survival analysis was also done in high- and low-risk subgroups. Low-risk patients are patients with INSS stage 1 or 2 without MYCN amplification, whereas high-risk patients are patients with INSS stage 4 tumor (irrespective of the MYCN gene status) or with INSS stage 2 or 3 tumor with MYCN amplification. A case control study was set up to validate the signature in the COG cohort. This was done to ensure a sufficientnumber of events in each risk group that is, to increase the power from what would have resulted from a random sample. Failure (cases) was defined as relapse, progression, or death from disease(pfs), and death(os) within a3-yearfollow-up period, andcontroldefined asnonfailure inthefirst 3 yearsof follow-up. Controls and cases with complete data were selected in a 2:1 ratio to increase the sample size and power. Multivariate logistic regression analyses were done to determine whether the signature was a significant independent predictor after controlling for known risk factors. Statistical analyses were done with SAS (version 9). The final logistic regression model used 50 cases and 100 randomly selected controls with complete data for PFS and 37 cases and 74 randomly selected controls with complete data for OS. Results Establishment of a prognostic mirna signature To establish and train a prognostic mirna signature, we used mirna expression data from 24 low-risk patients with a long PFS time and 27 deceased high-risk patients. Using the top 25 mirnas with the highest correlation with OS (Table 1), a 25 mirna expression signature was built. Table 1. Twenty-five mirnas in the prognostic signature Higher expressed in high-risk patients P value (univariate logistic regression) Higher expressed in low-risk patients P value (univariate logistic regression) hsa-mir E-04 hsa-mir-125b 9.16E-04 hsa-mir-18a 4.72E-04 hsa-mir-26a 1.19E-03 hsa-mir-18a 4.72E-04 hsa-mir E-04 hsa-mir-19a 4.93E-04 hsa-mir-30c 1.47E-04 hsa-mir-20a 3.31E-04 hsa-mir E-04 hsa-mir-20b 9.29E-04 hsa-mir E-04 hsa-mir-92a 8.95E-05 hsa-mir E-04 hsa-mir-15b 1.38E-04 hsa-mir E-05 hsa-mir E-04 hsa-mir-485-5p 9.00E-04 hsa-mir E-03 hsa-mir-542-3p 9.04E-04 hsa-mir-25 8E-04 hsa-mir E-04 hsa-mir E-04 hsa-mir E-04 hsa-mir E Clin Cancer Res; 17(24) December 15, 2011 Clinical Cancer Research
4 Prognostic MicroRNA Signature for Neuroblastoma Patients Further in the text, we will refer to this signature as a molecular indicator for low or high risk separating patients with low versus high risk. Validation of the prognostic 25-miRNA signature This 25 mirna expression signature significantly distinguished the remaining 179 patients of a first cohort of NB patients with respect to PFS and OS (P < 001; Fig. 1). PFS 5 years from the date of diagnosis was 84.3 (95% CI: ) for the group of patients with a molecular indicator for low risk, compared with 37.2 (95% CI: ) for the group of patients with a molecular indicator for high risk. The 5-year OS was 9% ( ) and 44.5% ( ) in the low and high molecular risk groups, respectively. Subsequently, we tested the signature within the group of low-risk NB patients with localized disease treated with surgery alone or in combination with mild chemotherapy and within the commonly defined high-risk group based on the different current risk stratification systems (Europe, United States, and Germany; ref. 13). Patients with increased risk for disease progression or relapse could be identified in both current low- and high-risk groups (P ¼ 14 and P ¼ 037, respectively). Although the signature was also useful in identifying those patients at increased risk for death in the current high-risk group (P ¼ 015), there was no difference in OS between patients with a molecular indicator for high and low risk in the current low-risk group (Fig. 2). Multivariate logistic regression analysis including the mirna signature, MYCN status, age at diagnosis and INSS stage, revealed that the mirna prognostic signature is an independent marker for both PFS and OS in the global cohort as well as in the high-risk subgroup (Table 2). Within the low-risk subgroup of patients the mirna classifier was shown to be an independent predictor for PFS (Table 2). The probability that a patient will be correctly classified by the signature based on a ROC-curve analysis (AUC) was 78.1% (95% CI: ) and 77.1% ( ) for OS and PFS, respectively. The signature predicted OS with a sensitivity of 83.0% (39/47) and a specificity of 73.3% (74/101). To validate the mirna signature in a second completely independent patient cohort, 304 COG tumors were tested in a blind manner. The same signature as used for the test cohort identified COG patients who were at greater risk for progression or relapse. Multivariate logistic regression analysis including the mirna signature, MYCN status, age, INSS stage, ploidy, International Neuroblastoma Pathology Classification (INPC), grade of differentiation, and mitosis karyorrhexis index (MKI) showed that the mirna signature was an independent significant predictor for PFS (OR 3.861, 95% CI: ). This was not the case for OS where the final logistic regression model involved only INSS stage and ploidy (Table 3). The mirna signature was also validated in 75 FFPE samples. mirna profiling was successful for 23 of the 25 mirnas in these archived samples. Prediction analysis using a 23-miRNA signature revealed comparable results as with the fresh frozen material. The signature successfully distinguished patients with good and poor outcome (P < 1; Fig. 3). Given the rather small cohort of samples, we did not substratify the patients in low- and high-risk groups based on the applied treatment protocols. However, multivariate logistic regression analysis was applied including the mirna signature, MYCN status, age at diagnosis, and INSS stage and showed that the signature is an independent predictor for both overall and event-free survival (Table 5). Comparison of the performances of the prognostic mirna signature with the prognostic 59 mrna signature To establish the prognostic value of this 25-miRNA signature in relation to our recently published 59-mRNA signature (2), we compared performances and prognostic power through survival analysis and multivariate analysis including both mirna and mrna signatures along with A PFS (P = 2.02e-10) B OS (P = 1.36e-10) Figure 1. Kaplan Meier and logrank analysis for progression-free (A) and overall (B) survival of the test cohort. The number of events is indicated between brackets. 99 (15) 79 (48) 99 (8) 80 (39) Clin Cancer Res; 17(24) December 15,
5 De Preter et al. A PFS high risk (P = 3.67e-03) B OS high risk (P = 1.46e-03) 27 (7) 27 (5) 63 (41) 64 (36) C PFS low risk (P = 1.43e-02) D OS low risk (P = 3.46e-01) 37 (2) 37 (4) 6 (1) Figure 2. Kaplan Meier and log-rank analysis for progression-free (A, C) and overall (B, D) survival within the low-risk treatment group (C, D) and within the high-risk treatment group (A, B). The number of events is indicated between brackets. 6 (3) other currently used risk factors on a common set of 122 test samples. Although, in a multivariate analysis, the 59-mRNA signature is an independent prognostic factor for both overall and PFS, the 25-miRNA signature is an independent prognostic factor for PFS but not for OS (Supplementary Table S1). Multivariate analysis including both signatures together with other currently used risk factors suggests that the 59-mRNA signature is an independent predictive factor for both overall and PFS whereas the 25-miRNA signature was not (Table 4). A possible explanation for this observation is the fact that the variation in mrna expression was significantly higher than the variation in mirna expression (Supplementary Fig. S1A, Mann Whitney, P < 001) in the tested patients, possibly allowing for a more robust separation between groups. When comparing the expression fold change between deceased patients and patients that are alive, we indeed observe a significantly higher fold change for mrna genes as compared with mirna genes (Supplementary Fig. S1B, Mann Whitney, P < 001). To exclude the possibility that we have established a suboptimal mirna classifier, we compared its performance with that of 2 published mirna classifiers (14, 15) and could show that both classifiers are less performant than the 25 mirna classier, and hence also do not outperform the 59 mrna classifier (Supplementary Table S1). Discussion Molecular risk classification of NB patients based on gene expression profiling is expected to contribute significantly to improved NB outcome prediction with the ultimate aim of tailoring the treatment to the severity of the disease. To this purpose, several mrna gene expression classifiers were previously developed (2, 13, 16 21). Given the fact that a single mirna, targeting several mrnas, may have broader effects than a single mrna and that mirnas are less sensitive to RNA degradation than mrnas, mirna classifiers might present with certain advantages compared with mrna classifiers. In this article, we successfully developed a mirna signature that was subsequently validated in the largest NB series till now containing both fresh frozen and archived FFPE material. Importantly, we show the ability of the signature to identify patients at ultra-high risk with respect to disease outcome within the current high-risk NB 7688 Clin Cancer Res; 17(24) December 15, 2011 Clinical Cancer Research
6 Prognostic MicroRNA Signature for Neuroblastoma Patients Table 2. Multivariate logistic regression analysis in the first test cohort including all patients, the low-risk patients, and the high-risk patients Variable P OR 95% CI on OR PFS (all patients, N ¼ 153) a mirna predictor (high vs. low risk) <001 5,737 2,463-13,360 Age at diagnosis (<>1 y) 018 4,261 1,715-10,587 INSS stage (stage 4 vs. not stage 4) 082 3,191 1,350-7,541 OS (all patients, N ¼ 147) a mirna predictor (high vs. low risk) Age at diagnosis (<>1 y) INSS stage (stage 4 vs. not stage 4) < PFS (low-risk patients, n ¼ 37) b mirna predictor (high vs. low risk) OS (low-risk patients, n ¼ 37) b No significant variables PFS (high-risk patients, n ¼ 68) a mirna predictor (high vs. low risk) INSS stage (stage 4 vs. not stage 4) OS (high-risk patients, n ¼ 63) a mirna predictor (high vs. low risk) a Variables tested in the model were mirna predictor, MYCN status, age, and INSS stage. b Variables tested in the model were mirna predictor and age. group for which no clinical or genetic markers are available today. To prove the robustness of a given signature, it should be validated under conditions that simulate the prospective broad clinical application of the assay and that reflect the various potential sources of assay variability, such as tissue handling, RNA extraction method, patient ethnicity, and treatment with other drugs. In this study, we conducted an external validation study on a completely independent cohort of COG patients whereby laboratory analyses were done blinded to clinical and outcome data. Also in this validation set, the signature was found to be a statistically significant independent risk predictor. For the mirna expression profiling, we used a highthroughput quantitative PCR-based stem-loop RT-primer method (7) along with a universally applicable data normalization method that had been successfully validated in our lab (8). Advantages of this method over the microarray technology are the higher cost-efficiency (definitely when measuring a 25-gene set), the shorter time to results, and the higher sensitivity (hence need of less input material). The use of a sample preamplification method enabled the maximization of the number of tumor samples available for this study through collaborative studies with international research laboratories; every laboratory could readily provide 100 ng of RNA. This is important, especially for pediatric cancers as biopsies are often very small and the material available limited. The use of a PCR-based method will definitely contribute to the development of a prognostic test that can be implemented in the clinic. Another important aspect for implementation of assays in the clinic is the type of starting material. In contrast to Table 3. Multivariate logistic regression analysis in the second validation cohort Variable a P OR 95% CI on OR PFS (n ¼ 113) mirna predictor (high vs. low risk b ) Grade (differentiating vs. undifferentiated and poorly differentiated b ) OS (n ¼ 78) INSS stage (stage 4 vs. not stage 4 b ) Ploidy (diploid vs. hyperdiploid b ) a Variables tested in the model were mirna predictor, MKI, MYCN status, age, ploidy, INSS stage, and grade. b Indicates the reference level for each variable. The OR is the increased risk of an event in comparison with this reference level. Clin Cancer Res; 17(24) December 15,
7 De Preter et al. A PFS (P = 6.87E-4) B OS (P = 3.82E-2) 48 (10) 26 (17) 48 (8) 27 (15) Figure 3. Kaplan Meier and log-rank analysis for progression-free (A) and overall (B) survival of the FFPE validation cohort. The number of events is indicated between brackets fresh frozen material, FFPE material might be a better alternative as starting material, because establishing an FFPE specimen from a primary tumor is a standardized and straightforward procedure that is accessible to any lab in any country in the world. Moreover, FFPE samples are stable at room temperature and are easily storable. To address this issue, we evaluated our mirna signature on 75 FFPE primary neuroblastoma tumors and successfully measured the expression of 23/25 mirnas in the signature. The 23- mirna signature was retrained on the initial test cohort of fresh frozen tumor samples and used to classify all FFPE samples. Importantly, the 23-miRNA signature allowed significant classification of patients with respect to overall and event-free survival in the FFPE cohort. This could not be achieved with the 59-mRNA signature due to extensive fragmentation of the mrna from FFPE material (data not shown). Strikingly, although the mirna signature was identified from and trained on fresh frozen tumor samples, it succeeded to classify FFPE samples. Not only does this underscore the robustness of the mirna signature, it also implies that FFPE and fresh frozen tumor samples can be grouped into one cohort when evaluating prognostic mirna signatures (i.e., when sample size of the patient cohort is too small to allow proper statistical analysis of a prognostic mirna signature). To our knowledge, this is the first report of a prognostic signature for neuroblastoma that has been validated on FFPE specimens. Given the fact that FFPE samples are widely available for all cancer types, these samples provide a vast resource to develop and validate mirna expression signatures. A prognostic classifier can be clinically useful without the understanding of the mechanistic relationship of the genes Table 4. Final backward-selected logistic regression model testing the mrna and mirna classifiers and covariates in validation set 1 and validation set 2. P OR 95% CI on OR Validation set 1 PFS (N ¼ 153) a mrna predictor (high vs. low risk d ) < Age at diagnosis (<> d 1 y) OS (N ¼ 147) a mrna predictor (high vs. low risk d ) < Age at diagnosis (<> d 1 y) INSS stage (stage 4 vs. not stage 4 d ) Validation set 2 PFS (N ¼ 113) b mrna predictor (high vs. low risk d ) Grade (differentiating vs. undifferentiated and poorly differentiated d ) OS (N ¼ 78) c mrna predictor (high vs. low risk d ) < a Variables tested in the model were age, stage, MYCN status, mrna classifier, mirna classifier. b Variables tested in the model and found not statistically significant were MYCN status, MKI, age, ploidy, the mirna classifier, INSS stage, and grade. c Variables tested in the model and found not statistically significant were the mirna classifier, age, MKI, MYCN status, and grade. d Indicates the reference level for each variable. The OR is the increased risk of an event in comparison to this reference level Clin Cancer Res; 17(24) December 15, 2011 Clinical Cancer Research
8 Prognostic MicroRNA Signature for Neuroblastoma Patients Table 5. Multivariate logistic regression analysis in the FFPE validation cohort Variable P OR 95% CI on OR PFS (n ¼ 65) a mirna predictor (high vs. low risk) 2.43E INSS stage (stage 4 vs. not stage 4) 1.47E OS (n ¼ 65) a mirna predictor (high vs. low risk) 7.24E INSS stage (stage 4 vs. not stage 4) 3.07E a Variables tested in the model were mirna predictor, MYCN status, age, and INSS stage. or the interpretation of the meaning of the individual genes included in the expression signature and clear biological elucidation might be more difficult to achieve than accurate classification (22). However, the presence of many genes implicated in NB biology in our recently published prognostic 59-mRNA signature (2) suggests that among the 25 mirnas in the present signature a significant portion may also be of direct biological relevance and may offer new opportunities for molecular therapy. As it is, all but one member of the mir cluster is part of the prognostic signature. These mirnas play a role in different tumorigenic pathways such as angiogenesis, cell adhesion and migration, cell-cycle regulation and proliferation, and negative regulation of apoptosis (23, 24). Furthermore, 16 of the 25 mirnas are MYC/MYCN driven (25). Mir-26a and mir-125b are potential targets for therapy as they are highly expressed in all normal tissues, are known tumor suppressor mirnas and candidates for replacement therapy (26). Gene ontology analysis of the 25 mirnas using the mirna body map ( showed a significant enrichment of GO terms for cell cycle, immune response, cell adhesion, and neuronal differentiation (Supplementary Table S2). Similar gene ontology classes are enriched in the 59 mrna gene set pointing at common biological processes that are represented by these prognostic classifiers. Furthermore, target analysis showed that several of the 25 mirnas target one or more of the 59 mrna genes (Supplementary Table S3). Further functional studies are required to show the possible mechanistic relevance of some of the 25 mirnas in NB pathogenesis. From these data, it is clear that the mirnas in our signature not only allow for a significant classification of patients with respect to good or poor prognosis but also seem to be associated with multiple key cancer pathways and might therefore be interesting targets for therapeutic intervention. In conclusion, the results obtained from this study clearly illustrate the power of mirna expression analysis in the risk classification of NB patients using both fresh frozen and archived tumor material. Importantly, the applied method and signature are suitable for routine laboratory testing worldwide. Disclosure of Potential Conflicts of Interest P. Mestdagh received commercial research support from Life Technologies. The other authors disclosed no potential conflicts of interest. Acknowledgments We thank Els De Smet, Nurten Yigit, Ga elle Van Severen, Justine Nuytens, Sander Anseeuw, and Liesbeth Vercruysse for their excellent technical assistance. We thank all members of the SIOPEN, GPOH, and COG for providing tumor samples or the clinical history of patients. Grant Support This work was supported by Ghent University Research Fund (BOF 01D31406; P. Mestdagh), the Fund for Scientific Research Flanders (K. De Preter), the Belgian Kid s Fund and the Fondation Nuovo-Soldati (J. Vermeulen), the FOD (NKP_29_014), the Fondation Fournier Majoie pour l Innovation, the Belgian Federal Public Health Service, the Association Hubert Gouin «Enfance et Cancer», the Flemish League against Cancer, the Children Cancer Fund Ghent, the Belgian Society of Paediatric Haematology and Oncology, the Fund for Scientific Research Flanders (grant number: G ), the Institute for the Promotion of Innovation by Science and Technology in Flanders, Strategisch basisonderzoek (IWT- SBO 60848), Children s Oncology Group grants (U10 CA98413 and U10 CA98543) and the Instituto Carlos III,RD 06/0020/0102 Spain. This article presents research results of the Belgian program of Interuniversity Poles of Attraction, initiated by the Belgian State, Prime Minister s Office, Science Policy Programming. We acknowledge the support of the European Community (FP6: STREP: EET-pipeline, number: ). R.L. Stallings was a recipient of grants from Science Foundation Ireland (07/IN.1/B1776), the Children s Medical and Research Foundation, and the NIH (5R01CA127496). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Received March 9, 2011; revised September 27, 2011; accepted October 13, 2011; published OnlineFirst October 26, References 1. Vermeulen J, De Preter K, Mestdagh P, Laureys G, Speleman F, Vandesompele J. Predicting outcomes for children with neuroblastoma. Dis Med 2010;10: Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIO- PEN/COG/GPOH study. Lancet Oncol 2009;10: Vermeulen J, De Preter K, Lefever S, Nuytens J, De Vloed F, Derveaux S, et al. Measurable impact of RNA quality on gene expression results from quantitative PCR. Nucleic Acids Res 2011;39:e63. Clin Cancer Res; 17(24) December 15,
9 De Preter et al. 4. Chen Y, Stallings RL. Differential patterns of microrna expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007;67: Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S, et al. Accurate prediction of neuroblastoma outcome based on mirna expression profiles. Int J Can J Int du Cancer 2010;127: Wang WX, Wilfred BR, Baldwin DA, Isett RB, Ren N, Stromberg A, et al. Focus on RNA isolation: obtaining RNA for microrna (mirna) expression profiling analyses of neural tissue. Biochimica et biophysica acta 2008;1779: Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F, et al. High-throughput stem-loop RT-qPCR mirna expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008;36:e Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microrna RT-qPCR data normalization. Genome Biol 2009;10:R Willems E, Leyns L, Vandesompele J. Standardization of real-time PCR gene expression data from independent biological replicates. Anal Biochem 2008;379: Lefever S, Hellemans J, Pattyn F, Przybylski DR, Taylor C, Geurts R, et al. RDML: structured language and reporting guidelines for real-time quantitative PCR data. Nucleic Acids Res 2009;37: Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99: Ruschhaupt M, Huber W, Poustka A, Mansmann U. A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol 2004;3:Article De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clinical cancer research: an official journal of the American Association for Can Res 2010;16: Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of mirna expression with survival. Plos One 2009;4:e Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S, et al. Accurate prediction of neuroblastoma outcome based on mirna expression profiles. Int J Cancer 2010;127: Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006;98: Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24: Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28: Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, et al. Expression profiling using a tumor-specific cdna microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005;7: Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005;24: Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Can Res 2004;64: Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005;23: Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microrna cluster. Nat Genet 2006;38: Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. Plos One 2008;3:e Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, et al. MYCN/c-MYC-induced micrornas repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010;29: Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microrna delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137: Clin Cancer Res; 17(24) December 15, 2011 Clinical Cancer Research
10 mirna Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples Katleen De Preter, Pieter Mestdagh, Joëlle Vermeulen, et al. Clin Cancer Res 2011;17: Published OnlineFirst October 26, Updated version Supplementary Material Access the most recent version of this article at: doi: / ccr Access the most recent supplemental material at: Cited articles Citing articles This article cites 26 articles, 6 of which you can access for free at: This article has been cited by 4 HighWire-hosted articles. Access the articles at: alerts Sign up to receive free -alerts related to this article or journal. Reprints and Subscriptions Permissions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. To request permission to re-use all or part of this article, use this link Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.
A novel and universal method for microrna RT-qPCR data normalization
A novel and universal method for microrna RT-qPCR data normalization Jo Vandesompele professor, Ghent University co-founder and CEO, Biogazelle 4 th International qpcr Symposium Weihenstephan, March 1,
More informationFrom reference genes to global mean normalization
From reference genes to global mean normalization Jo Vandesompele professor, Ghent University co-founder and CEO, Biogazelle qpcr Symposium USA November 9, 2009 Millbrae, CA outline what is normalization
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationmicrorna PCR System (Exiqon), following the manufacturer s instructions. In brief, 10ng of
SUPPLEMENTAL MATERIALS AND METHODS Quantitative RT-PCR Quantitative RT-PCR analysis was performed using the Universal mircury LNA TM microrna PCR System (Exiqon), following the manufacturer s instructions.
More informationSupplementary Material
Supplementary Material Identification of mir-187 and mir-182 as biomarkers for early diagnosis and prognosis in prostate cancer patients treated with radical prostatectomy Irene Casanova-Salas 1, José
More informationChapter 18. mirna Expression Profiling: From Reference Genes to Global Mean Normalization
Chapter 18 mirna Expression Profiling: From Reference Genes to Global Mean Normalization Barbara D haene, Pieter Mestdagh, Jan Hellemans, and Jo Vandesompele Abstract MicroRNAs (mirnas) are an important
More informationRoadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Richard Simon, J Clin Oncol 23:
Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Richard Simon, J Clin Oncol 23:7332-7341 Presented by Deming Mi 7/25/2006 Major reasons for few prognostic factors to
More informationA two-microrna signature in urinary exosomes for diagnosis of prostate cancer
Poster # B4 A two-microrna signature in urinary exosomes for diagnosis of prostate cancer Anne Karin Ildor Rasmussen 1, Peter Mouritzen 1, Karina Dalsgaard Sørensen 3, Thorarinn Blondal 1, Jörg Krummheuer
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Kratz JR, He J, Van Den Eeden SK, et
More informationDeploying the full transcriptome using RNA sequencing. Jo Vandesompele, CSO and co-founder The Non-Coding Genome May 12, 2016, Leuven
Deploying the full transcriptome using RNA sequencing Jo Vandesompele, CSO and co-founder The Non-Coding Genome May 12, 2016, Leuven Roadmap Biogazelle the power of RNA reasons to study non-coding RNA
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationPredicting clinical outcomes in neuroblastoma with genomic data integration
Predicting clinical outcomes in neuroblastoma with genomic data integration Ilyes Baali, 1 Alp Emre Acar 1, Tunde Aderinwale 2, Saber HafezQorani 3, Hilal Kazan 4 1 Department of Electric-Electronics Engineering,
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 33 NOVEMBER 11 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma
More informationPublished Ahead of Print on October 3, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on October 3, 11 as 10.10/JCO.11.35.9570 The latest version is at http://jco.ascopubs.org/cgi/doi/10.10/jco.11.35.9570 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
More informationDownregulation of serum mir-17 and mir-106b levels in gastric cancer and benign gastric diseases
Brief Communication Downregulation of serum mir-17 and mir-106b levels in gastric cancer and benign gastric diseases Qinghai Zeng 1 *, Cuihong Jin 2 *, Wenhang Chen 2, Fang Xia 3, Qi Wang 3, Fan Fan 4,
More informationCellecta Overview. Started Operations in 2007 Headquarters: Mountain View, CA
Cellecta Overview Started Operations in 2007 Headquarters: Mountain View, CA Focus: Development of flexible, scalable, and broadly parallel genetic screening assays to expedite the discovery and characterization
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME NUMBER 31 NOVEMBER 1 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Customized Oligonucleotide Microarray Gene Expression Based Classification of Neuroblastoma Patients Outperforms Current
More informationa) List of KMTs targeted in the shrna screen. The official symbol, KMT designation,
Supplementary Information Supplementary Figures Supplementary Figure 1. a) List of KMTs targeted in the shrna screen. The official symbol, KMT designation, gene ID and specifities are provided. Those highlighted
More informationA breast cancer gene signature for indolent disease
Breast Cancer Res Treat (2017) 164:461 466 DOI 10.1007/s10549-017-4262-0 EPIDEMIOLOGY A breast cancer gene signature for indolent disease Leonie J. M. J. Delahaye 1 Caroline A. Drukker 2,3 Christa Dreezen
More informationAssociation of microrna 21 With Biological Features and Prognosis of Neuroblastoma
Special Report Association of microrna 21 With Biological Features and Prognosis of Neuroblastoma Yaodong Zhou, MD, and Bo Sheng, MD Background: The aim of this study was to assess the differences in microrna
More informationPatnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies
Patnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies. 2014. Supplemental Digital Content 1. Appendix 1. External data-sets used for associating microrna expression with lung squamous cell
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Vermeulen J, Preter KD, Naranjo A, et
More informationAuthor's response to reviews
Author's response to reviews Title: Specific Gene Expression Profiles and Unique Chromosomal Abnormalities are Associated with Regressing Tumors Among Infants with Dissiminated Neuroblastoma. Authors:
More informationChromosome 1p and 11q Deletions and Outcome in Neuroblastoma
original article Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma Edward F. Attiyeh, M.D., Wendy B. London, Ph.D., Yael P. Mossé, M.D., Qun Wang, M.D., Ph.D., Cynthia Winter, B.A., Deepa Khazi,
More informationMolecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.
Innovation for your breast cancer diagnostics PGR G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C ERBB2
More informationmicrornas (mirna) and Biomarkers
micrornas (mirna) and Biomarkers Small RNAs Make Big Splash mirnas & Genome Function Biomarkers in Cancer Future Prospects Javed Khan M.D. National Cancer Institute EORTC-NCI-ASCO November 2007 The Human
More informationAuthor Manuscript Faculty of Biology and Medicine Publication
Serveur Académique Lausannois SERVAL serval.unil.ch Author Manuscript Faculty of Biology and Medicine Publication This paper has been peer-reviewed but dos not include the final publisher proof-corrections
More informationR2: web-based genomics analysis and visualization platform
R2: web-based genomics analysis and visualization platform Overview Jan Koster Department of Oncogenomics Academic Medical Center (AMC) UvA, the Netherlands jankoster@amc.uva.nl jankoster@amc.uva.nl 1
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationSimple, rapid, and reliable RNA sequencing
Simple, rapid, and reliable RNA sequencing RNA sequencing applications RNA sequencing provides fundamental insights into how genomes are organized and regulated, giving us valuable information about the
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationAugmented Medical Decisions
Machine Learning Applied to Biomedical Challenges 2016 Rulex, Inc. Intelligible Rules for Reliable Diagnostics Rulex is a predictive analytics platform able to manage and to analyze big amounts of heterogeneous
More informationMultiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma
RESEARCH ARTICLE Open Access Research article Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma Candy Kumps
More information95% CI: , P=0.037).
Biomedical Research 2017; 28 (21): 9248-9252 Reduced expression level of mir-205 predicts poor prognosis in Qiang Yang 1*#, Peng Sun 2#, Haotian Feng 1, Xin Li 1, Jianmin Li 1 1 Department of Orthopedics,
More informationOriginal Article Downregulation of microrna-26b functions as a potential prognostic marker for osteosarcoma
Int J Clin Exp Pathol 2016;9(6):6506-6510 www.ijcep.com /ISSN:1936-2625/IJCEP0024531 Original Article Downregulation of microrna-26b functions as a potential prognostic marker for osteosarcoma Zhihong
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationRNA-Seq profiling of circular RNAs in human colorectal Cancer liver metastasis and the potential biomarkers
Xu et al. Molecular Cancer (2019) 18:8 https://doi.org/10.1186/s12943-018-0932-8 LETTER TO THE EDITOR RNA-Seq profiling of circular RNAs in human colorectal Cancer liver metastasis and the potential biomarkers
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationGenome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
RESEARCH Open Access Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers Anneleen Decock 1, Maté Ongenaert 1, Jasmien Hoebeeck 1,2, Katleen De Preter
More informationPrognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification
Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification Shahab Asgharzadeh, Roger Pique-Regi, Richard Sposto, Hong Wang, Yujun Yang, Hiroyuki Shimada,
More informationModels of cell signalling uncover molecular mechanisms of high-risk neuroblastoma and predict outcome
Models of cell signalling uncover molecular mechanisms of high-risk neuroblastoma and predict outcome Marta R. Hidalgo 1, Alicia Amadoz 2, Cankut Çubuk 1, José Carbonell-Caballero 2 and Joaquín Dopazo
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationDiagnosis of multiple cancer types by shrunken centroids of gene expression
Diagnosis of multiple cancer types by shrunken centroids of gene expression Robert Tibshirani, Trevor Hastie, Balasubramanian Narasimhan, and Gilbert Chu PNAS 99:10:6567-6572, 14 May 2002 Nearest Centroid
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The National Surgical
More informationJ Clin Oncol 30: by American Society of Clinical Oncology INTRODUCTION
VOLUME 30 NUMBER 15 MAY 20 2012 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Douglas R. Strother, University of Calgary and Alberta Children s Hospital, Calgary, Alberta; Paul Thorner, Hospital
More informationAccepted Manuscript. Pancreatic Cancer Subtypes: Beyond Lumping and Splitting. Andrew J. Aguirre
Accepted Manuscript Pancreatic Cancer Subtypes: Beyond Lumping and Splitting Andrew J. Aguirre PII: S0016-5085(18)35213-2 DOI: https://doi.org/10.1053/j.gastro.2018.11.004 Reference: YGAST 62235 To appear
More informationGenomic explorations have offered us a great deal. Buried Treasure
18 Buried Treasure Noncoding DNA makes up the majority of our genomes, much of it being conserved and transcribed. Though the functions of small regulatory RNA molecules are well known, what about so-called
More informationmirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationThe Role of ploidy in neuroblastoma. Michael D. Hogarty, MD Division of Oncology Children s Hospital of Philadelphia
The Role of ploidy in neuroblastoma Reprinted from NB Journal Summer Issue 2003 Children s Neuroblastoma Cancer Foundation Michael D. Hogarty, MD Division of Oncology Children s Hospital of Philadelphia
More informationExpressArt FFPE Clear RNAready kit
Features and Example Results General problems with FFPE samples Formalin-fixation of tissues results in severe RNA fragmentation, as well as in RNA RNA, RNA-DNA and RNA protein cross-linking, which impairs
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationGene-Expression Profiling and the Future of Adjuvant Therapy
Gene-Expression Profiling and the Future of Adjuvant Therapy Marc van de Vijver Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands Key Words. Gene-expression profiling Prognostic
More informationExpression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 5525-5530 Expression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer Y.-X. SHI, B.-L. YE, B.-R. HU, X.-J.
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationBCL2 inhibition by ABT-199 in T-cell acute lymphoblastic leukemia (T-ALL)
BCL2 inhibition by ABT-199 in T-cell acute lymphoblastic leukemia (T-ALL) Pieter Van Vlierberghe Bioluminescent Cell-based Assay Seminar Day Monday 31 march 2014 UCL De Duve institute Brussels, Belgium
More informationMolecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.
Innovation for your breast cancer diagnostics Now valid ated on: -Roche cob as z 480 A nalyzer -Roche L ightcycle r 480 II - ABI 750 0 Fast -Versant kpcr Cyc ler PGR ESR1 MKI67 Molecular in vitro diagnostic
More informationPatient characteristics of training and validation set. Patient selection and inclusion overview can be found in Supp Data 9. Training set (103)
Roepman P, et al. An immune response enriched 72-gene prognostic profile for early stage Non-Small- Supplementary Data 1. Patient characteristics of training and validation set. Patient selection and inclusion
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationMir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer
European Review for Medical and Pharmacological Sciences 2017; 21: 4278-4282 Mir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer Q.-H. ZHOU 1, Y.-M. ZHAO 2, L.-L.
More informationCCG-3891 LONG TERM OUTCOME FOR CHILDREN WITH HIGH RISK NEUROBLASTOMA Additional Information on Corrected Overall Survival Results April 10, 2014
Group Chair Peter C. Adamson, M.D. adamson@email.chop.edu Group Vice Chair Susan Blaney, M.D. smblaney@txch.org Chief Operating Officer Elizabeth O Connor, M.P.H. econnor@childrensoncology group.org Chief
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationMammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU
MammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU 1 Bas van der Baan VP Clinical Affairs Irvine, California Amsterdam, The Netherlands 2 Two Crucial Questions in Cancer
More informationAccelerating Innovation in Statistical Design
Implementing a National Cancer Clinical Trials System for the 21 st Century, Workshop #2 Session #5: Accelerating Innovation Through Effective Partnerships Accelerating Innovation in Statistical Design
More informationSUPPLEMENTARY FIGURES AND TABLES
SUPPLEMENTARY FIGURES AND TABLES Supplementary Figure S1: CaSR expression in neuroblastoma models. A. Proteins were isolated from three neuroblastoma cell lines and from the liver metastasis of a MYCN-non
More informationFISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC
Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have
More informationEvaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value
Lehmann et al. BMC Cancer (2015) 15:179 DOI 10.1186/s12885-015-1102-7 RESEARCH ARTICLE Open Access Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic
More informationAssociation of mir-21 with esophageal cancer prognosis: a meta-analysis
Association of mir-21 with esophageal cancer prognosis: a meta-analysis S.-W. Wen 1, Y.-F. Zhang 1, Y. Li 1, Z.-X. Liu 2, H.-L. Lv 1, Z.-H. Li 1, Y.-Z. Xu 1, Y.-G. Zhu 1 and Z.-Q. Tian 1 1 Department of
More informationProfili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI
Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo BREAST CANCER Brain Adjuvant Medical Therapies
More informationStatistical Analysis of Biomarker Data
Statistical Analysis of Biomarker Data Gary M. Clark, Ph.D. Vice President Biostatistics & Data Management Array BioPharma Inc. Boulder, CO NCIC Clinical Trials Group New Investigator Clinical Trials Course
More informationSolomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationmir-125a-5p expression is associated with the age of breast cancer patients
mir-125a-5p expression is associated with the age of breast cancer patients H. He 1 *, F. Xu 2 *, W. Huang 1, S.Y. Luo 1, Y.T. Lin 1, G.H. Zhang 1, Q. Du 1 and R.H. Duan 1 1 The State Key Laboratory of
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Callegaro D, Miceli R, Bonvalot S, et al. Development
More informationGood Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers q
European Journal of Cancer 40 (2004) 1837 1841 European Journal of Cancer www.ejconline.com Good Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers
More informationProducts for cfdna and mirna isolation. Subhead Circulating Cover nucleic acids from plasma
MACHEREY-NAGEL Products for cfdna and mirna isolation Bioanalysis Subhead Circulating Cover nucleic acids from plasma n Flexible solutions for small and large blood plasma volumes n Highly efficient recovery
More informationdeveloping new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success
micrornas developing new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success Dr. Carola Wagner IMGM Laboratories GmbH Martinsried, Germany qpcr 2009 Symposium
More informationIdentifying Thyroid Carcinoma Subtypes and Outcomes through Gene Expression Data Kun-Hsing Yu, Wei Wang, Chung-Yu Wang
Identifying Thyroid Carcinoma Subtypes and Outcomes through Gene Expression Data Kun-Hsing Yu, Wei Wang, Chung-Yu Wang Abstract: Unlike most cancers, thyroid cancer has an everincreasing incidence rate
More informationTranscriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma
Published Online First on March 16, 2010 as 10.1158/1078-0432.CCR-09-2879 Imaging, Diagnosis, Prognosis Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma Clinical
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationOn the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles
On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles Ying-Wooi Wan 1,2,4, Claire M. Mach 2,3, Genevera I. Allen 1,7,8, Matthew L. Anderson 2,4,5 *, Zhandong Liu 1,5,6,7 * 1 Departments of Pediatrics
More informationLiposarcoma*Genome*Project*
LiposarcomaGenomeProject July2015! Submittedby: JohnMullen,MD EdwinChoy,MD,PhD GregoryCote,MD,PhD G.PeturNielsen,MD BradBernstein,MD,PhD Liposarcoma Background Liposarcoma is the most common soft tissue
More informationResearch Article Plasma HULC as a Promising Novel Biomarker for the Detection of Hepatocellular Carcinoma
BioMed Research International Volume 213, Article ID 13616, 5 pages http://dx.doi.org/1.1155/213/13616 Research Article Plasma HULC as a Promising Novel Biomarker for the Detection of Hepatocellular Carcinoma
More informationMicroarray Analysis and Liver Diseases
Microarray Analysis and Liver Diseases Snorri S. Thorgeirsson M.D., Ph.D. Laboratory of Experimental Carcinogenesis Center for Cancer Research, NCI, NIH Application of Microarrays to Cancer Research Identifying
More informationSerum mirna expression profile as a prognostic biomarker of stage II/III
Serum mirna expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma Jialu Li a,b,, Yang Liu c,, Cheng Wang d,, Ting Deng a,, Hongwei Liang b, Yifei Wang e, Dingzhi Huang
More informationDecreased expression of mir-490-3p in osteosarcoma and its clinical significance
European Review for Medical and Pharmacological Sciences Decreased expression of mir-490-3p in osteosarcoma and its clinical significance B. TANG, C. LIU, Q.-M. ZHANG, M. NI Department of Orthopedics,
More informationUK Liver Transplant Audit
November 2012 UK Liver Transplant Audit In patients who received a Liver Transplant between 1 st March 1994 and 31 st March 2012 ANNUAL REPORT Advisory Group for National Specialised Services Prepared
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationAssessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray
Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray Hui Chen, Aysegul A Sahin, Xinyan Lu, Lei Huo, Rajesh R Singh, Ronald Abraham, Shumaila Virani, Bal Mukund Mishra, Russell Broaddus,
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationMOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
MOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Ondrej Viklicky Department of Nephrology Transplant
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationReduced mirna-218 expression in pancreatic cancer patients as a predictor of poor prognosis
Reduced mirna-218 expression in pancreatic cancer patients as a predictor of poor prognosis B.-S. Li, H. Liu and W.-L. Yang Department of Gastrointestinal and Pancreatic Surgery, The Third Xiangya Hospital
More informationType of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures Supplementary Figure 1 mir-128-3p is highly expressed in chemoresistant, metastatic
More informationThe 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis
The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis Tieliu Shi tlshi@bio.ecnu.edu.cn The Center for bioinformatics
More informationCircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 3713-3718 CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer N. LIU 1, J. ZHANG 1, L.-Y. ZHANG 1, L.
More informationOriginal Article Reduced serum mir-138 is associated with poor prognosis of head and neck squamous cell carcinoma
Int J Clin Exp Pathol 2017;10(10):10276-10281 www.ijcep.com /ISSN:1936-2625/IJCEP0059849 Original Article Reduced serum mir-138 is associated with poor prognosis of head and neck squamous cell carcinoma
More information